Kleinschnitz, C.; Niemczyk, G.; Rehberg-Weber, K.; Wernsdörfer, C.
Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study. Int. J. Mol. Sci. 2015, 16, 15271-15286.
https://doi.org/10.3390/ijms160715271
AMA Style
Kleinschnitz C, Niemczyk G, Rehberg-Weber K, Wernsdörfer C.
Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study. International Journal of Molecular Sciences. 2015; 16(7):15271-15286.
https://doi.org/10.3390/ijms160715271
Chicago/Turabian Style
Kleinschnitz, Christoph, Gabriele Niemczyk, Karin Rehberg-Weber, and Colin Wernsdörfer.
2015. "Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study" International Journal of Molecular Sciences 16, no. 7: 15271-15286.
https://doi.org/10.3390/ijms160715271
APA Style
Kleinschnitz, C., Niemczyk, G., Rehberg-Weber, K., & Wernsdörfer, C.
(2015). Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study. International Journal of Molecular Sciences, 16(7), 15271-15286.
https://doi.org/10.3390/ijms160715271